Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Macaya Douoguih, Hein Fennema et al.|New England Journal of Medicine|2021Cited by 2.6k
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Macaya Douoguih, Glenda Gray et al.|New England Journal of Medicine|2022Cited by 250
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, Jeffrey J. Stoddard, An Vandebosch et al.|The Lancet Infectious Diseases|2022Cited by 88
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda Gray, Mookho Malahleha, Kathryn Mngadi et al.|The Lancet Infectious Diseases|2024Cited by 40